Ö. Türeci
Molecular Biology · 2013–2023
A researcher in the Science corpus: 17 papers; trusts 3 researchers and is trusted by 4 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 113 citations into it; #10,887 of 17,773 by trust here, #1,948 by citations
- Immunology — 107 citations into it
Whom Ö. Türeci trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Ö. Türeci overall
Papers from Ö. Türeci's perspective
Ordered by how strongly the researchers Ö. Türeci trusts endorse each paper. Same corpus, a different order for every researcher.
- Codon bias and heterologous protein expression. (Trends in Biotechnology)
- Highly efficient reprogramming to pluripotency and directed differentiation of human cells using synthetic modified mRNA (Cell Stem Cell)
- Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells (Nature Cell Biology)
- Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation (Nucleic Acids Research)
- Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. (Immunity)
- Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction (Nature Biotechnology)
- Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents (New England Journal of Medicine)
- 5'-Triphosphate RNA Is the Ligand for RIG-I
- AAV Vector Integration Sites in Mouse Hepatocellular Carcinoma (Science)
- Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.
Their papers
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer (2017) — 2,214 citations
- Mutant MHC class II epitopes drive therapeutic immune responses to cancer (2015) — 1,175 citations
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine (2020) — 11,263 citations
- mRNA-based therapeutics — developing a new class of drugs (2014) — 2,098 citations
- NCOA3 is a selective co-activator of estrogen receptor α-mediated transactivation of PLAC1 in MCF-7 breast cancer cells (2013) — 32 citations
- Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy (2016) — 1,560 citations
- Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents (2021) — 724 citations
- Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer (2023) — 1,108 citations
- BNT162b vaccines protect rhesus macaques from SARS-CoV-2 (2021) — 629 citations
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months (2021) — 1,225 citations
- BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) — 690 citations
- COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses (2020) — 1,578 citations
- An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma (2020) — 861 citations
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates (2020) — 2,193 citations
- Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults (2020) — 1,348 citations
- Concurrent human antibody andTH1 type T-cell responses elicited by a COVID-19 RNA vaccine (2020) — 87 citations
- Personalized vaccines for cancer immunotherapy (2018) — 966 citations